CORDIS
EU research results

CORDIS

English EN

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development

Project information

Grant agreement ID: 115009

Status

Closed project

  • Start date

    1 January 2010

  • End date

    31 December 2015

Funded under:

FP7-JTI

  • Overall budget:

    € 30 499 556

  • EU contribution

    € 9 658 388

Coordinated by:

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

Objective

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision before entering phase II trials for both symptomatic treatment and disease modifiers approaches. The hypothesis is that effective long term drugs will normalize markers artificially modified. The general objective is to test the efficiency of the 'matrix' on drug candidates for the enhancement/protection of cognitive functions. the final objective is to improve the detection and selection of new drugs candidates within a shorter teim-frame.
Our consortium gathers 13 academics and clinicians, 8 SMEs, 1 European patient organization (Alzheimer Europe) as well as 1 regulatory body (EMEA), coming form six different EU Members States. Excellence Centres gather representatives of the different sectors: biomarkers (proteomics, transcriptomics), pharmacodynamic markers ( electrophysiology, psychophysiology, morphological and functional imaging), preclinical model specialists (cellular, transgenic mouse, monkey), clinicians, and clinical pharmacologists.
By the end of this (-year project, the following achievements are expected; definition of the most predictive combination of pharmacodynamic markers; validation of parallel models (in healthy volunteers, ApoE 4 subjects,patients and animals) to establish effective exposure ranges and support proof of mechanism studies. The predictive value of the 'matrix' will be evaluated using different pharmacological target acting drugs. Suugestions for revised/new recomendations and guidellines will help to standardize the pre-clinical and clinical phases of drugs' development in neurodegenerative diseases.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

Address

Great West Road 980
Tw89gs Brentford

United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Jill C Richardson (Dr.)

Administrative Contact

Graham Ian Somers (Dr.)

Participants (37)

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 1 658 892

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 560 973

UNIVERSITE DE LILLE II - DROIT ET SANTE

France

EU Contribution

€ 1 066 828

UNIVERSITAET LEIPZIG

Germany

EU Contribution

€ 176 715

UNIVERSIDAD DE MURCIA

Spain

EU Contribution

€ 300 000

UNIVERSITAETSKLINIKUM ESSEN

Germany

EU Contribution

€ 70 748

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 205 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 1 010 591

UNIVERSITA DEGLI STUDI DI VERONA

Italy

EU Contribution

€ 360 000

PROVINCIA LOMBARDO VENETA - ORDINEOSPEDALIERO DI SAN GIOVANNI DI DIO- FATEBENEFRATELLI

Italy

EU Contribution

€ 767 507

UNIVERSITA DEGLI STUDI DI FOGGIA

Italy

EU Contribution

€ 448 496

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 549 000

Innovative Concepts in Drug Development (ICDD-sas)

France

EU Contribution

€ 298 423

SAS Alzprotect

France

EU Contribution

€ 304 377

Qualissima

France

EU Contribution

€ 544 752

Diaxonhit SA

France

EU Contribution

€ 259 677

Innovative Health Diagnostics

France

EU Contribution

€ 121 100

ALZHEIMER EUROPE

Luxembourg

EU Contribution

€ 100 000

ASTRAZENECA AB

Sweden

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

NOVARTIS PHARMA AG

Switzerland

INSTITUT DE RECHERCHES SERVIER

France

UCB PHARMA SA

Belgium

Merck KGaA

Germany

Eli Lilly and Company Limited

United Kingdom

JANSSEN PHARMACEUTICA NV

Belgium

F. HOFFMANN-LA ROCHE AG

Switzerland

H. LUNDBECK AS

Denmark

EISAI LIMITED

United Kingdom

UNIVERSITA DEGLI STUDI DI GENOVA

Italy

EU Contribution

€ 176 597

UNIVERSITY OF BRISTOL

United Kingdom

IRCCS FONDAZIONE SDN PER LA RICERCA E L'ALTA FORMAZIONE IN DIAGNOSTICA NUCLEARE

Italy

EU Contribution

€ 62 393

STICHTING VU

Netherlands

EU Contribution

€ 44 000

UNIVERSITA CATTOLICA DEL SACRO CUORE

Italy

EU Contribution

€ 62 400

ELLINIKI ETAIRIA NOSOY ALZHEIMER KAI SYGGENON DIATARACHON SOMATEIO

Greece

EU Contribution

€ 205 519

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

EU Contribution

€ 304 400

THE UNIVERSITY OF EXETER

United Kingdom

Project information

Grant agreement ID: 115009

Status

Closed project

  • Start date

    1 January 2010

  • End date

    31 December 2015

Funded under:

FP7-JTI

  • Overall budget:

    € 30 499 556

  • EU contribution

    € 9 658 388

Coordinated by:

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom